BE2011C041I2 - - Google Patents

Download PDF

Info

Publication number
BE2011C041I2
BE2011C041I2 BE2011C041C BE2011C041C BE2011C041I2 BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2 BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2
Authority
BE
Belgium
Application number
BE2011C041C
Other languages
French (fr)
Original Assignee
Bristol-Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co filed Critical Bristol-Myers Squibb Co
Publication of BE2011C041I2 publication Critical patent/BE2011C041I2/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2011C041C 2000-05-26 2011-11-10 BE2011C041I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (1)

Publication Number Publication Date
BE2011C041I2 true BE2011C041I2 (nl) 2020-08-20

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2011C041C BE2011C041I2 (nl) 2000-05-26 2011-11-10

Country Status (41)

Country Link
EP (3) EP1248802B9 (nl)
JP (1) JP4328525B2 (nl)
KR (2) KR100895134B1 (nl)
CN (2) CN1309735C (nl)
AR (1) AR031699A1 (nl)
AT (1) ATE271066T1 (nl)
AU (2) AU6346601A (nl)
BE (1) BE2011C041I2 (nl)
BR (1) BRPI0111191B8 (nl)
CA (1) CA2409748C (nl)
CY (2) CY2011019I2 (nl)
CZ (1) CZ304451B6 (nl)
DE (2) DE60104282T2 (nl)
DK (1) DK1248802T3 (nl)
EC (1) ECSP024365A (nl)
EE (2) EE05458B1 (nl)
EG (1) EG24459A (nl)
ES (2) ES2571852T3 (nl)
FR (1) FR11C0053I2 (nl)
GE (1) GEP20053658B (nl)
HK (2) HK1048126B (nl)
HU (2) HU228137B1 (nl)
IL (1) IL152315A (nl)
LT (1) LT5133B (nl)
LU (1) LU91902I2 (nl)
LV (1) LV12994B (nl)
MX (1) MXPA02011534A (nl)
MY (1) MY136113A (nl)
NO (2) NO330797B1 (nl)
PE (1) PE20011338A1 (nl)
PL (1) PL206267B1 (nl)
PT (1) PT1248802E (nl)
RU (1) RU2283847C2 (nl)
SI (1) SI1248802T1 (nl)
SK (1) SK288131B6 (nl)
TR (1) TR200402703T4 (nl)
TW (2) TWI314933B (nl)
UA (1) UA87432C2 (nl)
UY (1) UY26723A1 (nl)
WO (1) WO2001092337A2 (nl)
ZA (1) ZA200208944B (nl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
EP1372696B1 (en) * 2000-07-03 2008-07-23 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule
CA2447921C (en) 2001-05-23 2011-08-09 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
EP1496931A4 (en) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
EP1575998A4 (en) 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
SI1969007T1 (sl) * 2005-12-20 2014-03-31 Bristol-Myers Squibb Company Sestavki in postopki za izdelavo sestavka
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
WO2008079466A1 (en) 2006-12-20 2008-07-03 Mmr Information Systems, Inc. Antibodies and methods for making and using them
RU2506275C2 (ru) 2007-11-01 2014-02-10 Астеллас Фарма Инк. Иммуносупрессорные полипептиды и нуклеиновые кислоты
EP3281955A1 (en) * 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
TW201134481A (en) 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
EA201370187A1 (ru) 2011-02-23 2013-12-30 Амген Инк. Клеточная культуральная среда для уфс воздействия и относящиеся к ней способы
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
ES2777778T3 (es) * 2012-05-11 2020-08-06 Medimmune Ltd Variantes de CTLA-4
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
EP2866823A4 (en) * 2012-06-27 2016-03-02 Orban Biotech Llc CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
US10513723B2 (en) 2014-01-13 2019-12-24 Amgen Inc. Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
BR112016028285B1 (pt) 2014-06-04 2023-02-23 Amgen Inc Método para uma colheita periódica prolongada, sistema de filtro de unidade única e método para cultivo de células que expressam proteína recombinante
EA202091598A3 (ru) 2014-12-01 2021-01-29 Эмджен Инк. Процесс контроля уровня содержания гликанов в составе
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
CA2982246A1 (en) 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
CN108350416A (zh) 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
EP3515489A4 (en) * 2016-09-19 2020-05-06 Oncoimmune, Inc. CD80 AND CD86 BINDING PROTEIN COMPOSITIONS AND USES THEREOF
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
KR20200074137A (ko) 2017-10-10 2020-06-24 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
AU2020338947A1 (en) 2019-08-27 2022-03-31 Tonix Pharma Limited Modified TFF2 polypeptides
BR112021025769A2 (pt) 2019-12-06 2022-04-12 Regeneron Pharma Composições de proteína anti-vegf e métodos para a produção das mesmas
EP4168807A1 (en) 2020-06-18 2023-04-26 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed c-terminal lysine
US20230287322A1 (en) 2020-07-28 2023-09-14 Seagen Inc. Methods and systems for producing polypeptides
WO2023115027A2 (en) 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
WO2023167850A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
JP2003532370A (ja) * 1998-10-07 2003-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 新規なTh2特異的分子およびその使用方法
EP1372696B1 (en) * 2000-07-03 2008-07-23 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule

Also Published As

Publication number Publication date
NO330797B1 (no) 2011-07-18
LT2002114A (en) 2003-12-29
EP1536234A2 (en) 2005-06-01
DE60104282T2 (de) 2005-10-13
JP2004511213A (ja) 2004-04-15
BR0111191A (pt) 2004-07-06
KR20030009502A (ko) 2003-01-29
MXPA02011534A (es) 2004-08-12
KR100895134B1 (ko) 2009-05-04
FR11C0053I2 (fr) 2013-01-11
IL152315A0 (en) 2003-05-29
EP1248802B1 (en) 2004-07-14
NO2011027I2 (nl) 2011-12-15
AU2001263466C1 (en) 2006-10-26
EP1248802B9 (en) 2005-05-11
PL206267B1 (pl) 2010-07-30
EG24459A (en) 2009-07-16
CY1117625T1 (el) 2017-04-26
PT1248802E (pt) 2004-11-30
HU228137B1 (en) 2012-12-28
UY26723A1 (es) 2001-12-28
UA87432C2 (uk) 2009-07-27
EE05557B1 (et) 2012-08-15
HUP0302201A3 (en) 2010-01-28
DK1248802T3 (da) 2004-11-15
CZ20023892A3 (cs) 2003-09-17
EE200200659A (et) 2004-06-15
WO2001092337A2 (en) 2001-12-06
DE122011100063I1 (de) 2012-06-14
PE20011338A1 (es) 2002-01-13
HK1048126B (zh) 2005-03-04
CY2011019I1 (el) 2016-12-14
CA2409748C (en) 2008-09-16
EP1536234B1 (en) 2016-03-16
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
BRPI0111191B8 (pt) 2021-05-25
LV12994B (en) 2003-08-20
SI1248802T1 (en) 2005-02-28
ES2571852T3 (es) 2016-05-27
NO2011027I1 (no) 2012-01-09
ES2225549T3 (es) 2005-03-16
TR200402703T4 (tr) 2004-11-22
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
TWI319405B (en) 2010-01-11
JP4328525B2 (ja) 2009-09-09
CN101255192A (zh) 2008-09-03
GEP20053658B (en) 2005-11-10
EP1536234A3 (en) 2009-06-03
BRPI0111191B1 (pt) 2019-12-31
DE60104282D1 (de) 2004-08-19
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
HUS1300012I1 (hu) 2016-08-29
HK1071931A1 (zh) 2005-08-05
IL152315A (en) 2010-04-15
ECSP024365A (es) 2003-03-31
HK1048126A1 (en) 2003-03-21
MY136113A (en) 2008-08-29
ATE271066T1 (de) 2004-07-15
AR031699A1 (es) 2003-10-01
NO20025656D0 (no) 2002-11-25
TWI314933B (en) 2009-09-21
EE201100050A (et) 2011-10-17
TW200906857A (en) 2009-02-16
EE05458B1 (et) 2011-08-15
KR100889887B1 (ko) 2009-03-24
CA2409748A1 (en) 2001-12-06
PL366231A1 (en) 2005-01-24
AU2001263466B2 (en) 2006-04-27
LT5133B (lt) 2004-05-25
EP3029062A1 (en) 2016-06-08
RU2283847C2 (ru) 2006-09-20
HUP0302201A2 (hu) 2003-10-28
SK15702002A3 (sk) 2004-01-08
AU6346601A (en) 2001-12-11
ZA200208944B (en) 2004-02-13
NO20025656L (no) 2002-11-25
FR11C0053I1 (nl) 2012-01-13
CN1441810A (zh) 2003-09-10
CN1309735C (zh) 2007-04-11
CZ304451B6 (cs) 2014-05-14

Similar Documents

Publication Publication Date Title
BE2013C060I2 (nl)
FR11C0053I1 (nl)
AU2000236815A8 (nl)
JP2003515707A5 (nl)
JP2001238443A5 (nl)
BY5768C1 (nl)
IN191510B (nl)
IN189075B (nl)
CN3148479S (nl)
CN3142150S (nl)
CN3143796S (nl)
CN3143853S (nl)
CN3136262S (nl)
CN3143905S (nl)
CN3135921S (nl)
CN3144584S (nl)
CN3144671S (nl)
CN3143422S (nl)
CN3144700S (nl)
CN3145461S (nl)
CN3147656S (nl)
CN3147984S (nl)
CN3143069S (nl)
CN3135584S (nl)
CN3149245S (nl)